HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE

This article was originally published in The Rose Sheet

Executive Summary

The battle between hazard and risk ideologies goes on as NGO Women’s Voices for the Earth calls for the removal of five fragrance ingredients from personal-care products that FDA recently – if reluctantly – struck from its list of approved food additives. The agency maintains the substances pose no risk to public health.

You may also be interested in...



Breast Cancer NGO Slams Fragrance Industry, Big Brands, Celebs, With ‘Secret Chemicals’ Report

Nearly 80% of the “toxins” detected in the Breast Cancer Prevention Partners’ cosmetics analysis were fragrance chemicals undeclared (lawfully) on product labeling, according to the NGO, which seeks regulatory changes to mandate full ingredient disclosure. Industry is calling the report misinformation, but it’s garnering media attention and being cited by the sponsor of a new cosmetic reform bill in the House.

P&G To Disclose Fragrance Ingredients Portfolio-Wide By 2020

NGOs are trumpeting P&G's fragrance disclosure announcement as a major victory for public health and a turning point for the entire consumer products industry. The initiative, which follows a similar move from Unilever in February, will provide visibility into fragrance formulae across more than 2,000 P&G products.

PCPSA's 'No Harm' Standard Would Set High Bar For FDA Ingredient Review

Regulatory consultants have concerns about the draft Personal Care Products Safety Act's proposed standard for FDA ingredient review – reasonable certainty of no harm. The standard's de facto application in FDA's review of new dietary ingredients in the supplement space has resulted in a fail rate of around 75%.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel